Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three business segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a range of instruments, consumables, services and software that are primarily used by customers to study genomics and the basic building blocks of life, including deoxyribonucleic acid (DNA)and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
高配当
同社は高配当銘柄であり、最新の配当性向は20.13%です。
安定配当
同社は過去5年間にわたり継続的に配当を実施しており、最新の配当性向は20.13%です。
適正水準
同社の最新のPEは38.99で、過去3年間の水準と比較して適正圏にあります。
機関投資家の買い増し
最新の機関投資家の保有株数は670.76M株で、前四半期比で0.05%増加しています。
バンガードが保有
スター投資家バンガードは本銘柄を60.48M株保有しています。
市場活動が低調
同社への投資家の関心は低下しており、20日間の売買回転率は-0.06です。